New publication by Giuseppina Carbone’s Prostate Cancer Biology group

A new study, published in the journal Cancers describes a novel approach to dissect the intrinsic heterogeneity of prostate tumors and provide predictive information on clinical outcome and treatment response in clinical samples and experimental models. This prostate-specific metagene approach can improve treatment selection and clinical management of prostate cancer patients. Sarah N. Mapelli, Domenico Albino, Maurizia Mello-Grand, Dheeraj Shinde, Manuel Scimeca, Rita Bonfiglio, Elena Bonann...
More

Mitochondrial reprogramming heads stem cell expansion and castration-resistance in prostate cancer – New grant awarded to Prof. Carlo Catapano

New grant awarded by the Swiss Cancer League to the Tumor Biology and Experimental Therapeutics Group headed by the IOR Director Prof. Carlo Catapano. The 3-year project aims at exploring the role of mitochondria in prostate cancer progression and resistance to current therapies. Project details Project ID: KLS-4899-08-2019 PI: Carlo Catapano Project title: Mitochondrial dynamics at the crossroad between stemness and treatment resistance in prostate cancer Prostate cancer is one of...
More

Combinatorial nanomedicines for precision therapy of prostate cancer at the IOR – New grant awarded to Prof. Carlo Catapano

New grant awarded to the Tumor Biology and Experimental Therapeutics Group headed by the IOR Director Prof. Carlo Catapano (http://www.ior.usi.ch). The project Nanoparticle-based delivery and combinatorial therapies for cancer funded by SNSF in the context of the European COST action on Cancer Nanomedicine (CA17140) aims at developing new nanoparticle-based medicine for precision therapy of advanced prostate cancer. The project involves scientific partners in Turkey (Prof. Rana Sanyal, Dep...
More

Full professorship at ETH Zurich granted to Prof. Dr. Andrea Alimonti

Professor Andrea Alimonti, MD, group leader at the Institute of Oncology Research (IOR, affiliated with USI) and Full professor at the USI Faculty of Biomedical Sciences, has been appointed by the ETH Board as Full professor of Experimental oncology and translational cancer medicine at the ETH Zurich. https://www.usi.ch/en/feeds/12525 https://ethz.ch/en/news-and-events/eth-news/news/2019/12/new-professors.html
More

Robert Wenner Prize to Andrea Alimonti

The Swiss Cancer League has awarded this year's Robert Wenner Prize for young cancer researchers to Andrea Alimonti. With his work, the researcher and doctor has discovered how cancer cells age - and how this so-called senescence can be used therapeutically. More information on the Robert Wenner Prize
More

Prostate cancer, accolades for two IOR researchers

A research project on prostate cancer conducted at the Institute of Oncology Research (IOR, affiliated to USI), won a PCF Challenge Award 2019 worth $1 million at the annual conference of the PCF Prostate Cancer Foundation, the leading U.S. agency in the field, on October 25 in Carlsbad, California. The study of the international research team, led by Prof. Andrea Alimonti, group leader at the IOR and Full professor at the USI Faculty of Biomedical Sciences, was published in the prestigious scie...
More